Navigation Links
YM BioSciences third quarter 2010 operational and financial results
Date:5/13/2010

MISSISSAUGA, ON, May 13 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, TSX:YM), today reported operational and financial results for the third quarter of fiscal 2010, ended March 31, 2010.

"During the third quarter, we completed the merging into YM of Cytopia Limited, now YM BioSciences Australia, expanding our pipeline through the addition of two promising new drug candidates in drug classes that have been established as being of high interest and value to the pharmaceutical industry," said David Allan, Chairman and CEO of YM BioSciences. "With a strengthened balance sheet from our recent financing and a portfolio of four late-stage products, the quality and prospects for our drug portfolio are unmatched in YM's history as a company. This quarter we gathered momentum in for our clinical programs with an expansion of our Phase I/II clinical trial for CYT387 as well as the acceptance and presentation of our data at several international forums. We look forward to numerous clinical and corporate events during the balance of 2010."

Highlights for the third quarter of Fiscal 2010:

    -   Merged Cytopia (now YM BioSciences Australia), a clinical-stage, drug
        development company based in Melbourne, Australia, into YM.

    -   Cleared by the US FDA to enroll patients at US clinical sites into
        two ongoing randomized, double-blind Phase II trials of our lead
        product, nimotuzumab.

    -   Expanded the current Phase I/II clinical trial in myelofibrosis
        through an earlier-than-planned initiation of the Phase II component
        of the study for CYT387, the company's highly selective and potent
        JAK1/2 inhibitor.

    -   Had two posters accepted for presentation at the American Association
        for Cancer Resear
'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
2. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
3. YM BioSciences announces controlled equity offering
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
5. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
6. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
7. YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
8. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
9. YM BioSciences closes US$17.5 million financing
10. YM BioSciences to raise approximately US$15 million
11. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... of what happens on the surface of cells. The ... A group of researchers from Lund University in Sweden ... a large number of vertical nanowires, known as a ... cell and its surroundings takes place through the cell ... the cell together and that largely comprises lipids, built ...
(Date:9/2/2014)... AVENTURA, Fla. , Sept. 2, 2014  Technology ... has announced that its wholly-owned subsidiary Renuell Int,l, Inc. ... National Aeronautics and Space Administration ("NASA") at the Johnson ... See photos: tapplic.com/houstonphotos/ ... stated, "We are very pleased to announce our latest, ...
(Date:9/2/2014)... 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ) announced ... Executive Officer, will present at the Rodman & Renshaw 16 ... York on Tuesday, Sept. 9, 2014 at 2:05 ... of the presentation will be accessible by visiting the Oncothyreon ... About Oncothyreon Oncothyreon is ...
(Date:9/2/2014)... , September 2, 2014 Culot ... research and lab management services  BioData, producer ... is pleased to announce the appointment of Louis ... recently served as VP Marketing and Business Development at ... research and clinical applications. Previously, Culot worked ...
Breaking Biology Technology:Nano-forests to reveal secrets of cells 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Louis Culot Appointed as BioData's CEO 2
... ... Delay, LEXINGTON, Mass., ... Glenn L. Cooper,MD, its chairman and chief executive officer is postponing his,previously-announced ... of the recent delay in the approval of NEBIDO(R)., Dr. Cooper ...
... Raymond J. De,Hont, Chairman and Chief Executive Officer ... Fybroc business unit has received,an order for approximately $500,000 ... second and third quarters of the Company,s current fiscal ... order Fybroc has received this year from the,Eastern European ...
... Cell Therapeutics, Inc.,(Nasdaq and MTA: CTIC) today announced that ... million, newly issued 15% Convertible,Senior Notes due 2011, with ... warrant to purchase approximately 14.6 million shares of common ... This transaction constitutes a partial exercise of a previously ...
Cached Biology Technology:Indevus Announces Management Changes 2Indevus Announces Management Changes 3Indevus Announces Management Changes 4Met-Pro Corporation's Fybroc Business Unit Receives Equipment Order Totaling Approximately $500,000 2Met-Pro Corporation's Fybroc Business Unit Receives Equipment Order Totaling Approximately $500,000 3Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor 2
(Date:9/2/2014)... New research suggests that professional baseball pitchers with poor ... days in a single season because of injury than are ... back and pelvis. , In the study, 347 pitchers were ... tilt in their pelvis as they raised a leg to ... miss at least 30 days cumulative, not consecutive ...
(Date:9/2/2014)... study published in the September issue of ... a novel strategy to diagnose the leading cause ... structural damage has occurred. This advance involves quantifying ... the endothelium of retinal vessels. Using new probes ... the early molecular development of diabetic retinopathy. , ...
(Date:9/2/2014)... Best-selling author Sam Kean stops by Reactions this ... 50-foot super shark that, despite what "Shark Week" may ... about it at http://youtu.be/KhFygIoW_MA . , Kean,s book, ... Love and the History of the World from the ... treatment in a 10-episode video series produced for the ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... optogenetics, the researchers are able to target one cell ... to find out exactly what goes wrong in the ... Prof. Dr. Stefan Herlitze (RUB Department for Biology and ... Biological Chemistry . The Bochum team examined a specific ...
... MD FASEB MARC (Minority Access to Research Careers) ... 2011 Society for Leukocyte Biology (SLB) Meeting in Kansas ... are meant to promote the entry of underrepresented minority ... basic science community and to encourage the participation of ...
... - Researchers speaking on the final day of the 6th ... 2011) have focused on the growing interest in the scientific ... have been growing over the past 12 months and are ... Society (IAS) convened working group concentrating its initial efforts on ...
Cached Biology News:Controlling movements with light 2 Researchers present new trends in HIV cure research, call for proactive outreach programs to prevent HIV transmission in injecting drug users, and demand increased commitments to improving maternal and child health 2 Researchers present new trends in HIV cure research, call for proactive outreach programs to prevent HIV transmission in injecting drug users, and demand increased commitments to improving maternal and child health 3 Researchers present new trends in HIV cure research, call for proactive outreach programs to prevent HIV transmission in injecting drug users, and demand increased commitments to improving maternal and child health 4
... polyclonal to Neuron navigator 1 ( Abpromise ... Synthetic peptide conjugated to KLH derived from ... Neuron navigator 1. (Note: the amino acid ... as ab32208 .) Entrez ...
Na+/H+ exchanger, isoform NHE1....
Anti-Potassium Channel EAG-1 Immunogen: Synthetic peptide from the C-terminus of rat Kv10.1 (Accession Q63472). The immunogen sequence is identical in mouse and 14/16 residues identical in human...
Mouse monoclonal [DAPK-55] to DAP Kinase 1 ( Abpromise for all tested applications). entrezGeneID: 1612 SwissProtID: P53355...
Biology Products: